Saturday 17 October 2026
Export HRTX’s income statement to Excel — free account
Heron Therapeutics, Inc.
HRTX Healthcare Biotechnology
Heron Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $154.9 million, up 7.36% from fiscal 2024. In the quarter to June 2026, revenue grew 1.25%, EPS fell 93.6%, free cash flow grew 78.8% and total debt fell 18.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.36
0.02
−5.26%
Follow HRTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.54 | 1.01 | 1.40 | 1.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(36.98) | (98.52) | (23.60) | 161.26 | |
P/B ratio |
13.97 | 18.76 | 16.32 | 30.56 | |
Price to Tangible BV |
13.97 | 18.76 | 16.32 | 30.56 | |
EV/Sales |
1.20 | 1.65 | 2.01 | 1.93 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 78.04 | |
EV/Operating CF |
(15.67) | (12.27) | (11.26) | (9.90) | |
EV/FCF |
(15.04) | (11.95) | (11.17) | (9.63) | |
Quick Ratio |
1.44 | 1.42 | 1.42 | 1.52 | |
Current Ratio |
2.49 | 2.53 | 2.48 | 2.56 | |
Net Debt/EBITDA |
(65.95) | (23.28) | 136.24 | (24.67) | |
Debt/Assets |
56.55% | 57.52% | 54.96% | 56.10% | |
Debt/Equity |
20.65 | 15.50 | 9.81 | 9.38 | |
Asset Turnover |
0.62 | 0.63 | 0.63 | 0.66 | |
Operating CF/Net income |
0.40 | 0.19 | 3.11 | (0.08) | |
Capex/Depreciation |
(0.26) | (0.65) | 0.02 | 0.04 | |
Research and Development Expense of Revenue |
7.17% | 6.87% | 9.23% | 9.08% | |
Selling, General and Administrative Expense of Revenue |
67.53% | 76.21% | 63.28% | 70.45% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.44% | 8.57% | 5.37% | 7.46% | |
Graham Net Nets |
(0.19) | (0.05) | (0.02) | (0.02) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(44.19%) | (21.94%) | (8.88%) | (5.99%) | |
Free Cash Flow Yield |
(14.77%) | (13.71%) | (12.83%) | (14.46%) | |
Revenue per Share |
0.20 | 0.18 | 0.24 | 0.22 | |
Operating CF per Share |
(0.01) | (0.01) | (0.06) | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | (0.01) | (0.05) | 0.01 | |
Cash per Share |
0.22 | 0.24 | 0.28 | 0.33 | |
Shareholders Equity per Share |
0.04 | 0.05 | 0.09 | 0.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.04 | 0.05 | 0.09 | 0.09 | |
Free Cash Flow |
(2.35) | (1.93) | (9.17) | 1.36 | |
Working Capital |
137.70 | 138.47 | 141.97 | 139.69 | |
Capital Expenditures |
(0.14) | (0.39) | 0.02 | 0.03 | |
Net Current Asset Value |
(15.51) | (8.09) | (3.48) | (4.66) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 187.11 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 134.40 | |
| Other line items | |||||
Average Receivables |
84.75 | 81.21 | 84.23 | 74.04 | |
Average Payables |
11.84 | 10.65 | 10.35 | 11.10 | |
Average Inventory |
81.78 | 74.74 | 72.95 | 57.99 | |
Average Assets |
242.18 | 240.98 | 244.51 | 234.86 | |
Average Common Equity |
(10.70) | (10.18) | (10.18) | (16.49) |
Columns are period end dates